The FDA turned down an Intercept Pharmaceuticals drug application for the fatty liver disease NASH, a decision that comes nearly three years after the regulator first rejected the molecule. The agency ...

A therapeutic being tested for nonalcoholic steatohepatitis (NASH) and liver fibrosis showed statistically significant improvement versus placebo on two primary endpoints in a one-year, Phase 2b trial ...

The unmet need in non-alcoholic steatohepatitis (NASH) is getting bigger and bigger. In the decade up to 2032, the number of diagnosed cases in seven major markets is forecast to grow by 4.5 million, ...

Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to ...

MASH is the updated term for NASH to decrease stigma and improve understanding. The name change links liver disease to metabolic factors, which improves diagnosis and treatment. Challenges include ...

Please provide your email address to receive an email when new articles are posted on . In a multicenter study, researchers identified two novel protein biomarkers (PLIN2 and RAB14) that demonstrated ...

Researchers have created a liquid biopsy test, which uses two circulating proteins, to test for major liver diseases. The test was found to be highly accurate, sensitive, and specific for both NASH ...

Liver disease researchers, stumped by a complex disease, are looking for new investigative tools. Artificial intelligence might be one of them. At a small conference of the American Association for ...

Akero Therapeutics said Tuesday that an experimental medicine improved liver scarring at twice the rate of a placebo without worsening other symptoms — achieving the main goal of a mid-stage clinical ...

WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and ...